Co-Diagnostics' High-Stakes Push to Bring PCR Power to the Clinic

SALT LAKE CITY, UT – July 01, 2026 – In the world of medical diagnostics, the Polymerase Chain Reaction (PCR) test is the undisputed gold standard, a benchmark for accuracy that has traditionally been confined to the sophisticated infrastructure of centralized laboratories. That paradigm may be on the verge of a significant shift. Co-Diagnostics, a Utah-based molecular diagnostics firm, announced today the completion of a massive slate of clinical and analytical studies for its point-of-care respiratory test, a critical milestone that paves the way for a planned submission to the U.S. Food and Drug Administration (FDA) in the third quarter of this year.

The submission is not just for a new test, but for a new way of testing. The company is seeking both 510(k) clearance and a Clinical Laboratory Improvement Amendments (CLIA) Waiver for its Co-Dx™ PCR Flu A/B & RSV multiplex test, designed to run on its compact Co-Dx PCR Pro® instrument. If successful, this dual clearance would effectively liberate high-accuracy PCR technology from the lab, placing it directly into the hands of clinicians in doctors' offices, urgent care centers, and pharmacies across the country.

The Gold Standard Leaves the Lab

For decades, healthcare has operated on a trade-off between speed and accuracy in diagnostics. Rapid antigen tests can provide an answer in minutes but often lack the sensitivity to catch early or low-level infections, leading to false negatives. Conversely, lab-based PCR tests are highly reliable but introduce a delay of hours, or even days, between sample collection and a result—a critical window when treatment decisions and infection control measures are most effective.

Co-Diagnostics aims to shatter this compromise. The company's platform is designed to deliver a definitive result for Influenza A, Influenza B, and RSV from a single patient sample in under 40 minutes. For a parent with a sick child or a physician managing a patient with respiratory symptoms, this speed is transformative. It means moving beyond educated guesses and initiating targeted antiviral therapies, implementing appropriate isolation protocols, and avoiding the unnecessary prescription of antibiotics—a key driver of antimicrobial resistance—all within a single visit.

“Completing both the analytical and clinical performance studies for the upper respiratory test is a significant execution milestone for Co-Diagnostics,” said Dwight Egan, the company's Chief Executive Officer, in a statement. He emphasized the sheer scale of the undertaking, which involved over 1,400 symptomatic patients across nine U.S. clinical sites and more than 10,000 test runs in 27 separate analytical studies. This isn't just about proving the test works; it's about proving it works consistently, everywhere, and for everyone.

Navigating the Regulatory Gauntlet

Securing a 510(k) clearance from the FDA is a rigorous process, requiring a company to demonstrate its device is “substantially equivalent” to a legally marketed predicate device. However, simultaneously pursuing a CLIA Waiver elevates the challenge exponentially. A waiver signifies that the FDA deems a test so simple and with such an insignificant risk of an erroneous result that it can be performed by personnel without formal laboratory training.

This is the holy grail for point-of-care diagnostics, and the bar is exceptionally high, especially for a technology as complex as PCR. To clear it, Co-Diagnostics had to prove its system could be operated reliably by the intended users. The company conducted a rigorous external multicenter reproducibility study where untrained operators across different sites used multiple instruments. According to Egan, the results demonstrated the consistency required for a waiver.

“That consistency is central to what a CLIA Waiver requires and to our broader vision of bringing accurate, near-patient PCR diagnostics to decentralized settings,” Egan noted. This study is the linchpin of the company's strategy, providing the data-driven argument that its platform is not just powerful, but also foolproof enough for the real world.

A High-Stakes Bet in a Crowded Field

Co-Diagnostics is making its move in a fiercely competitive market. Industry giants like Abbott, with its widely adopted ID NOW™ molecular platform, and Cepheid, with its powerful GeneXpert® system, already command significant market share. These established players have set a high bar for performance and usability in the point-of-care space.

Furthermore, Co-Diagnostics is navigating this path from a challenging financial position. With revenues declining over the past year and a market capitalization that reflects investor caution, the company is burning through cash to fund its ambitious R&D and regulatory efforts. This makes the upcoming FDA submission a pivotal, make-or-break moment. Success would not only validate its core technology but could unlock a multi-billion-dollar market and dramatically reshape the company's financial trajectory. Failure would be a significant setback.

The company is betting that its unique technological approach can carve out a winning position. While competitors offer molecular solutions, Co-Diagnostics argues its platform offers true, gold-standard PCR performance in a format simple enough for the broadest possible range of healthcare settings, a potential differentiator if proven and cleared by the FDA.

The Technology Behind the Ambition

At the heart of the Co-Dx platform is a proprietary and patented chemistry known as Co-Primers®. This technology is engineered to reduce a common flaw in PCR reactions called “primer dimers,” which can lead to inaccurate results. By fundamentally enhancing the specificity and sensitivity of the reaction, this technology provides the robust foundation needed to build a reliable point-of-care device.

This advanced chemistry is packaged into a deceptively simple “test cup.” This self-contained system includes all the necessary reagents, minimizing manual steps and reducing the potential for user error or contamination—a critical design element for a CLIA-waived product. The user experience is further simplified through a mobile app interface that guides the operator and displays the results.

This is not the company’s first foray into the FDA process for its new platform. It previously submitted, and later withdrew, a 510(k) application for a COVID-19 test to address FDA feedback on shelf-life stability. That experience, while a delay, has likely provided invaluable lessons for the current, more complex dual submission. With its vast body of clinical and analytical data now complete, Co-Diagnostics is preparing to make its case to regulators, and the outcome will be a defining moment for the company and a potential inflection point for the future of decentralized diagnostics.